Jianjun Fan

Jianjun Fan

Auto-generated profile, based on publicly available information

Jianjun Fan

Basic Medicine Research and Innovation Center for Novel Target and Therapeutic Intervention, Ministry of Education, Institute of Life Sciences, the Second Affiliated Hospital of Chongqing Medical University, Chongqing Medical University, Chongqing 400010, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2024 in Science
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
JJJingjing Jiang
Jingjing Jiang
SDShao-Yue Du
Shao-Yue Du
LMLiangshan Mu
Liangshan Mu
JFJian-Jun Fan
Jian-Jun Fan
QTQi-Qun Tang
Qi-Qun Tang
Polycystic ovary syndrome (PCOS), a prevalent reproductive disorder in women of reproductive age, features androgen excess, ovulatory dysfunction, and polycystic ovaries. Despite its high prevalence, specific pharmacologic intervention for PCOS is challenging. In this study, we identified artemisinins as anti-PCOS agents. Our finding demonstrated the efficacy of artemisinin derivatives in alleviating PCOS symptoms in both rodent models and human patients, curbing hyperandrogenemia through suppression of ovarian androgen synthesis. Artemisinins promoted cytochrome P450 family 11 subfamily A member 1 (CYP11A1) protein degradation to block androgen overproduction. Mechanistically, artemisinins directly targeted lon peptidase 1 (LONP1), enhanced LONP1-CYP11A1 interaction, and facilitated LONP1-catalyzed CYP11A1 degradation. Overexpression of LONP1 replicated the androgen-lowering effect of artemisinins. Our data suggest that artemisinin application is a promising approach for treating PCOS and highlight the crucial role of the LONP1-CYP11A1 interaction in controlling hyperandrogenism and PCOS occurrence.

1 January 2021 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JFJianjun Fan
Jianjun Fan
YXYang Xiao
Yang Xiao
MQMatthias Quick
Matthias Quick
YYYuwei Yang
Yuwei Yang
ZSZiyi Sun
Ziyi Sun
XZXiaoming Zhou
Xiaoming Zhou
The neurotransmitter:sodium symporter (NSS) homolog LeuT from Aquifex aeolicus has proven to be a valuable model for studying the transport mechanism of the NSS family. Crystal structures have captured LeuT in key conformations visited during the transport cycle, allowing for the construction of a nearly complete model of transport, with much of the conformational dynamics studied by computational simulations. Here, we report crystal structures of LeuT representing new intermediate conformations between the outward-facing open and occluded states. These structures, combined with binding and accessibility studies, reveal details of conformational dynamics that can follow substrate binding at the central substrate-binding site (S1) of LeuT in outward-facing states, suggesting a potential competition for direction between the outward-open and outward-occluded states at this stage during substrate transport. Our structures further support an intimate interplay between the protonation state of Glu290 and binding of Na1 that may ultimately regulate the outward-open-to-occluded transition.

14 November 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
WXWenlong Xu
Wenlong Xu
YWYuqi Wang
Yuqi Wang
NZNa Zhang
Na Zhang
XLXiaofeng Lin
Xiaofeng Lin
DZDi Zhu
Di Zhu
YDYongjun Dang
Yongjun Dang
Aberrant N-linked glycosylation is a prominent feature of cancers. Perturbance of oligosaccharide structure on cell surfaces directly affects key processes in tumor development and progression. In spite of the critical role played by N-linked glycans in tumor biology, the discovery of small molecules that specifically disturbs the N-linked glycans is still under investigation. To identify more saccharide-structure-perturbing compounds, a repurposed drug screen by using a library consisting of 1530 FDA-approved drugs was performed. Interestingly, an antipsychotic drug, penfluridol, was identified as being able to decrease cell surface wheat germ agglutinin staining. In the presence of penfluridol, cell membrane glycoproteins programmed death-ligand 1 (PD-L1) shifted to a lower molecular weight. Further studies demonstrated that penfluridol treatment caused an accumulation of high-mannose oligosaccharides, especially Man5–7GlcNAc2 glycan structures. Mechanistically, this effect is due to direct targeting of MAN1A1 mannosidase, a Golgi enzyme involved in N-glycan maturation. Moreover, we found that altered glycosylation of PD-L1 caused by penfluridol disrupted interactions between programmed cell death protein 1 and PD-L1, resulting in activation of T-cell tumor immunity. In a mouse xenograft and glioma model, penfluridol enhanced the antitumor effect of the anti–PD-L1 antibody in vivo. Overall, these findings revealed an important biological activity of the antipsychotic drug penfluridol as an inhibitor of glycan processing and proposed a repurposed use of penfluridol in antitumor therapy through activation of T-cell immunity.

17 June 2026
Verified
Other
Open access
PDF file
WXWenlong Xu
Wenlong Xu
YWYuqi Wang
Yuqi Wang
NZNa Zhang
Na Zhang
XLXiaofeng Lin
Xiaofeng Lin
DZDi Zhu
Di Zhu
YDYongjun Dang
Yongjun Dang
(a) Western blot analysis of glycoprotein patterns in MDA-MB-231 cells after treatment with the indicated concentrations of penfluridol for 24 hours. Red arrowhead, immature glycoproteins. (b) Western blot analysis of protein expression pattern of ACE2 in HEK293T cells after treatment with the indicated concentrations of penfluridol for 24 hours. (c) In HEK293T cells, FLAG-tagged ACE2 was treated for 24 hours, collected by immunoprecipitation, subjected to SDS-PAGE, and analyzed by western blot. (d) Pearson correlation coefficient of three independent groups of (c) through N-glycan profiling.

17 June 2026
Verified
Other
Open access
WXWenlong Xu
Wenlong Xu
YWYuqi Wang
Yuqi Wang
NZNa Zhang
Na Zhang
XLXiaofeng Lin
Xiaofeng Lin
DZDi Zhu
Di Zhu
YDYongjun Dang
Yongjun Dang
(a) Western blot analysis of protein expression pattern of PD-L1 in HEK293T cells after the exposure to the indicated concentrations of penfluridol for 24 hours. (b) Protein expression pattern of PD-L1 in B16-F10 cells after treatment with the indicated concentrations of penfluridol for 12 hours as determined by western blot. (c) The toxicity effect of penfluridol on B16-F10 (top) and B16-OVA (bottom) cells. (d) Western blot analysis of protein expression of MAN1A1 in B16-OVA cells treated with the indicated siRNA.

17 June 2026
Verified
Other
Open access
WXWenlong Xu
Wenlong Xu
YWYuqi Wang
Yuqi Wang
NZNa Zhang
Na Zhang
XLXiaofeng Lin
Xiaofeng Lin
DZDi Zhu
Di Zhu
YDYongjun Dang
Yongjun Dang
(a) The stability of proteins was determined by cellular thermal shift at different concentrations of penfluridol.